BiotechTube

SHR-1210+GEMOX

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer, Cholangiocarcinoma

Trial Timeline

Feb 10, 2018 → Nov 30, 2020

NCT ID
NCT03486678

About SHR-1210+GEMOX

SHR-1210+GEMOX is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Biliary Tract Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03486678. Target conditions include Biliary Tract Cancer, Cholangiocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03486678Phase 2Completed

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
41
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
52
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
52
E6011 + PlaceboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
SHR-A1811Jiangsu Hengrui MedicinePhase 2
52
SHR1258Jiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
77
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
23
durvalumabAstraZenecaPhase 3
77
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
65
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + TremelimumabAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85